Electromed, Inc.(ELMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #852 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ELMD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Electromed, Inc. (ELMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ELMD at 60.5/100 on a 32-signal composite quality model, placing it at rank #852 of 2,962 stocks — the top half of the AI-ranked universe. ELMD scores in the top quartile across balance sheet strength (96.2), profitability (77.9). Areas of concern include revenue scale (12.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Electromed, Inc. reports quarterly revenue of $19.4M, net income of $3.4M, an operating margin of 19.7%. Top institutional holders of ELMD by reported 13-F value include J.E. Simmons & , P.C., BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ELMD trades on the NYSE exchange and files with the SEC under CIK 1488917. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Electromed, Inc. directly from SEC EDGAR. Electromed, Inc.'s 13F Pro composite quality score has ranged between 35 and 68 since 2021, currently 60.5 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$19.4M
Net Income
Q2 2026
$3.4M
Free Cash Flow
Q2 2026
$2.8M
Operating Margin
Q2 2026
19.7%
ROIC
Q2 2026
28.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+15.3% YoYNet Income
+49.9% YoYOperating Income
+43.7% YoYEPS (Diluted)
+52.9% YoYTotal Assets
+23.2% YoYTotal Debt
Op. Cash Flow
-15.2% YoYFree Cash Flow
-24.4% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $73.8M +15.3% | $64.0M +17.0% | $54.7M +13.8% | $48.1M +15.4% | $41.7M +16.5% | $35.8M |
| Net Income | $11.3M +49.9% | $7.5M +46.3% | $5.2M +62.7% | $3.2M +37.4% | $2.3M -2.4% | $2.4M |
| Operating Income | $13.9M +43.7% | $9.7M +46.8% | $6.6M +64.2% | $4.0M +34.9% | $3.0M -5.4% | $3.1M |
| EPS (Diluted) | $1.30 +52.9% | $0.85 +46.6% | $0.58 +61.1% | $0.36 +38.5% | $0.26 -3.7% | $0.27 |
| Total Assets | $66.3M +23.2% | $53.8M +3.0% | $52.2M +14.0% | $45.8M +10.7% | $41.4M +11.5% | $37.1M |
| Total Debt | — | — | — | — | — | $33.0K |
| Operating Cash Flow | $9.7M -15.2% | $11.4M +25.7% | $9.1M +589.5% | $1.3M +291.7% | $-686.0K -122.3% | $3.1M |
| Free Cash Flow | $8.4M -24.4% | $11.1M +26.8% | $8.8M +2736.6% | $-333.0K +84.2% | $-2.1M -175.7% | $2.8M |
Get alerted when ELMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Electromed, Inc. including:
Top Institutional Holders of ELMD
J.E. Simmons & Co., P.C.
$20.5M483,822 shBlackRock, Inc.
$19.7M465,619 shVANGUARD CAPITAL MANAGEMENT LLC
$12.0M283,232 shACADIAN ASSET MANAGEMENT LLC
$9.4M221,845 shPUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
$9.2M218,520 shGEODE CAPITAL MANAGEMENT, LLC
$9.2M217,115 shDIMENSIONAL FUND ADVISORS LP
$7.6M180,447 shTWO SIGMA INVESTMENTS, LP
$7.1M167,492 shHUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC
$6.6M155,878 shGAMCO INVESTORS, INC. ET AL
$6.0M142,000 sh
| Fund | Value | Shares |
|---|---|---|
| J.E. Simmons & Co., P.C. | $20.5M | 483,822 |
| BlackRock, Inc. | $19.7M | 465,619 |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.0M | 283,232 |
| ACADIAN ASSET MANAGEMENT LLC | $9.4M | 221,845 |
| PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. | $9.2M | 218,520 |
| GEODE CAPITAL MANAGEMENT, LLC | $9.2M | 217,115 |
| DIMENSIONAL FUND ADVISORS LP | $7.6M | 180,447 |
| TWO SIGMA INVESTMENTS, LP | $7.1M | 167,492 |
| HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC | $6.6M | 155,878 |
| GAMCO INVESTORS, INC. ET AL | $6.0M | 142,000 |
Companies Similar to ELMD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
PRO DEX INC
Protalix BioTherapeutics, Inc.
IRADIMED CORP
VIEMED HEALTHCARE, INC.
LEMAITRE VASCULAR INC
NATURES SUNSHINE PRODUCTS INC
TACTILE SYSTEMS TECHNOLOGY INC
Niagen Bioscience, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ELMD on your watchlist
Track score changes the day Electromed, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ELMD a good stock to buy?
13F Pro's AI-powered analysis of Electromed, Inc. (ELMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELMD are available on the ELMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ELMD is classified as a small company.
Which hedge funds own ELMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Electromed, Inc.'s investment landscape.